What is it about?
High flow nasal cannula (HFNC) is a respiratory supportive therapy that has been used in the overall management of the acute respiratory failure. One of the concerns related during its use is to not delay the initiation of more aggressive treatments, such as invasive mechanical ventilation. In the present article, we validate the use of the ROX index that can help identify both those HFNC patients with low and those with high risk for intubation.
Featured Image
Why is it important?
This is the first study that describes and validates values at different time-points of the ROX index to predict need for invasive mechanical ventilation of respiratory failure patients treated with high flow nasal cannula.
Perspectives
Delayed intubation of spontaneously breathing patients with hypoxemic acute respiratory failure is associated with an excess mortality. In the present study we confirm the ROX accuracy for predciting nasal high flow oxygen outome in patients with pneumonia.
Oriol Roca
Read the Original
This page is a summary of: An Index Combining Respiratory Rate and Oxygenation to Predict Outcome of Nasal High-Flow Therapy, American Journal of Respiratory and Critical Care Medicine, June 2019, American Thoracic Society,
DOI: 10.1164/rccm.201803-0589oc.
You can read the full text:
Contributors
The following have contributed to this page
